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Abstract
Despite promising developments in computational tools, peptide-class II MHC (MHCII)
binding predictors continue to lag behind their peptide-class I MHC counterparts. Conse-
quently, peptide–MHCII binding is often evaluated experimentally using competitive bind-
ing assays, which tend to sacrifice throughput for quantitative binding detail. Here, we
developed a high-throughput semiquantitative peptide–MHCII screening strategy termed
microsphere-assisted peptide screening (MAPS) that aims to balance the accuracy of com-
petitive binding assays with the throughput of computational tools. Using MAPS, we
screened a peptide library from Zika virus envelope (E) protein for binding to four common
MHCII alleles (DR1, DR4, DR7, DR15). Interestingly, MAPS revealed a significant overlap
between peptides that promiscuously bind multiple MHCII alleles and antibody neutraliza-
tion sites. This overlap was also observed for rotavirus outer capsid glycoprotein VP7,
suggesting a deeper relationship between B cell and CD4+ T cell specificity which can
facilitate the design of broadly protective vaccines to Zika and other viruses.
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1 | INTRODUCTION
Zika virus is a type of flavivirus, which is a family of structurally similar
enveloped viruses transmitted by ticks and mosquitoes. The primary
antigenic target on flaviviruses including Zika virus is the envelope
(E) protein, which binds to host cell receptors and mediates virus
entry.1 The Zika virus E protein has three domains, EDI (residues
1–52, 132–193, and 280–296), EDII (residues 52–132 and 193–280),
and EDIII (residues 296–406)2 and is highly similar to the E protein of
other flaviviruses, ranging from 39.5% similarity for tick-borne
encephalitis to 57.8% similarity for dengue virus 1 .3
Because the Zika virus E protein is similar to the E protein of other
flaviviruses, antibodies that bind E protein are often cross-reactive.
However, rather than neutralizing a heterologous flavivirus infection,
these cross-reactive antibodies tend to exacerbate the infection by
promoting the internalization and replication of virus in Fc-receptor
expressing cells.4 This phenomenon, known as antibody-dependent
enhancement (ADE), can be life threatening and underscores the
importance of eliciting a highly specific, neutralizing antibody
response against E protein in areas where multiple flaviviruses circu-
late. A number of recent studies have shown that antibodies targeting
the EDIII domain of the Zika virus E protein tend to be potently neu-
tralizing2,5,6 and less cross-reactive with E proteins from other
flaviviruses than antibodies targeting EDI or EDII.2 Therefore, the
EDIII domain of Zika virus E protein is of special interest for Zika virus
vaccine development.
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Although a robust and neutralizing antibody response generally cor-
relates with flavivirus immunity, less is known about the contribution of
T cells to clearing flavivirus infection. However, it was recently shown
that CD4+ T cell signaling plays a fundamental role in sustaining
antibody-mediated resistance to Zika virus infection.7 In addition, it is
thought that T cells play an important role in clearing flavivirus infections
from the central nervous system (CNS).8,9 In a recent study, it was shown
that no antibodies are present in the CNS during persistent Zika virus
infection in nonhuman primates, and decreased Zika viral load in the
CNS correlated with the initiation of a CD8+ T cell response.10 This
observation is especially interesting considering that while most individ-
uals infected with Zika virus are asymptomatic, serious neurological com-
plications including microcephaly11 and Guillain-Barre syndrome12 have
been observed at rates up to 1 in 100 and 1 in 5,000 infections, respec-
tively.13 Because a targeted T cell response to Zika virus could play a role
in mitigating these neurological complications as well as sustaining the
production of neutralizing antibodies, the identification of both CD8+
and CD4+ T cell epitopes within Zika virus proteins is an active area of
research.14
However, before a T cell can recognize a specific antigenic peptide,
that peptide must first be presented by a major histocompatibility com-
plex (MHC) molecule. Both class I and class II MHC molecules (MHCI and
MHCII, respectively) present peptides through interactions between spe-
cific peptide residues (termed the peptide binding register, or PBR) and
the MHC peptide-binding groove. MHC molecules are highly polymor-
phic15,16 and most of the genetic diversity is manifested in the peptide-
binding groove of different MHC alleles. As a result, different MHC
alleles generally exhibit different binding specificities.17 Because the fre-
quency of MHC alleles varies among ethnically diverse populations,
immunodominant peptides from viral18 proteins capable of promiscu-
ously binding multiple MHC alleles are of considerable interest for
broadly protective peptide-based therapuetics.19-21
Over the past 20 years, several in silico strategies have been
devised to identify such promiscuous MHCII-binding peptides includ-
ing matrix based methods,22,23 structure based methods,24-27 and
machine learning methods using artificial neural networks.28-31 The
accuracy of in silico peptide–MHC binding predictors is measured by
the area under (AUC) the receiver operating characteristic (ROC)
curve, with a value of 1 indicating a perfect prediction and a value of
0.5 indicating a completely random prediction. Currently, machine
learning methods using artificial neural networks are among the most
accurate in silico predictors, achieving an AUC of approximately
0.85–0.95 for peptide–MHCI binding predictions and 0.75–0.85 for
peptide–MHCII binding predictions.32 The accuracy of peptide–MHC
binding predictors can often be improved by combining the top-
performing individual predictors into a consensus method,33,34 which
is the strategy recommended by the Immune Epitope Database and
Analysis Resource (IEDB).35 Although in silico peptide–MHCII binding
predictors perform well during cross-validation with standardized
datasets, they tend to underperform when applied to new datasets or
datasets containing peptides of different lengths.31 In a study of
21 different peptide–MHCII binding predictors, no individual predic-
tor was found to be suitable for the prediction of promiscuous
MHCII-binding peptides.17 Moreover, these predictors were charac-
terized by high false-positive rates and even the most accurate could
only identify 50% of actual T cell epitopes from four antigenic protein
libraries.17
Given the limited accuracy and high false-positive rate of in silico
peptide-MHCII binding predictors, a demand exists for high-throughput
systems capable of reliably identifying promiscuous MHCII-binding pep-
tides. To this end, a wide range of experimental methods have been
applied to measure peptide-MHCII binding, including ELISA,36,37 fluores-
cence polarization,38 gel-filtration with radiolabeled peptides,36,39 fluo-
rescence resonance energy transfer,40,41 surface plasmon resonance
(SPR),42 cell-surface display,43 and bead-based methods.44 While many
of these techniques are well established and yield quantitative peptide-
MHCII binding data, the vast majority tend to sacrifice throughput in
favor of quantitative detail. For example, competition based assays like
ELISA,36,37 fluorescence polarization,38 and some bead-based methods44
involve titrating the target peptide for competitive binding with a labeled
reference peptide. Although the quantitative binding data derived from
these competition assays is critical to improving in silico peptide-MHCII
binding prediction algorithms, they typically involve 8–12 point titrations
in triplicate for reliable data. The amount of MHCII protein required for
competitive binding assays could be greatly reduced, and the study of
peptide-MHCII binding made more efficient, if a preliminary screening
strategy were used to identify MHCII binding peptides from a large
library of nonbinders using a binary classification scheme. Once identi-
fied, these MHCII binding peptides could be further studied in detail.
Here, we developed and validated a high-throughput, semiquanti-
tative assay for prescreening MHCII binding peptides termed
microsphere-assisted peptide screening (MAPS). MAPS was designed
to strike a balance between the quantitative detail offered by conven-
tional competition-based binding assays and the throughput offered
by in silico predictors by directly measuring peptide-MHCII binding
using flow cytometry. Using MAPS, we identified five peptides within
the Zika virus E protein that promiscuously bound four common
human MHCII alleles including DR1, DR4, DR7, and DR15. Of the five
promiscuous MHCII-binding peptides identified, IEDB in silico binding
predictors predicted only one, suggesting that computational peptide-
MHCII binding predictors alone may miss a significant number of pro-
miscuous MHCII-binding peptides. In addition, we observed a sub-
stantial overlap between promiscuous MHCII-binding peptides and
antibody neutralization sites in the Zika virus E protein. A similar over-
lap was also observed for the rotavirus outer capsid glycoprotein VP7.
Taken together, these results demonstrate that MAPS is a reliable,
high-throughput method for rapidly identifying promiscuous MHCII-
binding peptides.
2 | MATERIALS AND METHODS
2.1 | Protein design, expression, and peptide
synthesis
Human MHCII proteins were assembled by isolating the extracellular
domains of the alpha chain HLA-DRA (UniProt: P01903, residues 26–216)
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and each beta chain allele: HLA-DRB1*01:01 (UniProt: P04229, residues
30–227), HLA-DRB1*04:01 (UniProt:P13760, residues 30–227), HLA-
DRB1*07:01 (UniProt: P13761, residues 30–227), HLA-DRB1*15:01
(UniProt: P01911, residues 30–227). The leucine zipper dimerization
motifs Fos and Jun were fused to the C-terminus of the DRA and DRB1
chains, respectively, as described elsewhere.45 The 15 amino acid AviTag™
(GLNDIFEAQKIEWHE) was fused to the C-terminus of the Fos dimeriza-
tion motif on the DRA chain to allow for biotinylation, and a 6X-Histidine
tag was fused to the C-terminus of the complete recombinant DRA chain
for purification. The N-terminus of each DRB1 chain was fused to the
invariant chain CLIP87-101 peptide via a thrombin-cleavable linker to allow
for peptide exchange, as described elsewhere.46 The C-terminus of the
Jun-dimerization motif of each DRB1 was fused to a 6X-Histidine tag for
purification. Finally, the N-terminus of each dimeric chainwas fused to the
baculovirus gp64 signal peptide and ligated into separate baculovirus
transfer vectors pAcGP67A (BaculoGold Baculovirus Expression System,
Pharmingen BD Biosciences, San Jose, CA). The DNA sequence of each
construct was verified by Sanger sequencing.
Spodoptera frugiperda (Sf9) insect cells were transfected with
transfer vectors carrying the recombinant DRA chain and each recom-
binant beta chain (DR1, DR4, DR7, and DR15) with linearized
Baculovirus DNA (Pharmingen BD BaculoGold Biosciences, San Jose,
CA) using Cellfectin II (Invitrogen, Waltham, MA) according to the
manufacturer's protocol. Low-titer P0 viral stocks carrying the recom-
binant DRA and DRB1 genes were isolated from the transfection
supernatant and amplified separately in Sf9 cells to create high-titer
P1 viral stocks. Each human MHCII heterodimer was expressed by
coinfecting High-Five cells at a density of 2.0M/mL with equal vol-
umes of high-titer P1 DRA and DRB1 baculovirus stocks. MHCII pro-
tein was harvested 72 hr after infection and purified using affinity
chromatography with Ni-NTA beads according to the manufacturer's
protocol (Qiagen). SDS-PAGE analysis was performed to evaluate pro-
tein purity.
Approximately 0.5 mg of each peptide used in this work was
chemically synthesized by Sigma-Aldrich (Woodlands, TX). Each pep-
tide was designed to be 20 amino acids long and was fused to an N-
terminal dinitrophenyl (DNP) tag. Peptide libraries covering the Bur-
kholderia pseudomallei alkyl hydroperoxide reductase (AhpC) protein
(UniProt: Q63T73 residues, 1–180), the rotavirus outer capsid glyco-
protein VP7 (UniProt: P11853 residues 41–320), and the Zika virus E
protein (UniProt: A0A024B7W1 residues 291–794) were designed
such that each 20mer peptide overlapped with the preceding peptide
in the sequence by 10 amino acids. DNP-tagged variants of
DR1-binding peptide the HA306-318 were also synthesized to deter-
mine how relative PBR position affects MAPS signal. Peptides in the
libraries that could not be chemically synthesized were not included in
the MAPS analysis, and explain any nonconsecutive sequences in Fig-
ures S3 and S4.
2.2 | Biotinylation and peptide exchange
After purifying the human MHCII-CLIP proteins, the DRA chain of
each heterodimer was biotinylated. Biotinylation reactions were
performed with the AviTag™ biotinylation kit (Avidity LLC, Aurora,
CO) according to the manufacturer's protocol. The biotinylation effi-
ciency for each allele was assessed using a streptavidin gel-shift assay.
Briefly, biotinylated MHCII-CLIP proteins were incubated with excess
streptavidin for 1 hr at 30C. The complexes were then analyzed using
SDS-PAGE, and biotinylation efficiency was evaluated by estimating
the fraction of the biotinylated DRA chain that shifted following incu-
bation with streptavidin.
Peptide exchange was performed similar to previously published
methods,47 with some modifications. Prior to peptide exchange, the
CLIP87-101 peptide fused to each DR beta chain was cleaved. CLIP87-101
cleavage was performed by incubating the MHC-CLIP protein with
restriction grade thrombin (Novagen, Madison, WI) for 2 hr at 37C at a
concentration of 10 units per milligram of protein. Thrombin-induced
CLIP87-101 cleavage was confirmed using SDS-PAGE (Figure S1c). Fol-
lowing CLIP87-101 cleavage, peptide exchange was performed by trans-
ferring the empty DR alleles into peptide exchange buffer containing
50 mM sodium citrate pH 5.2, 1% octylglucoside, and 100 mM NaCl. DR
alleles were then incubated with 25M excess DNP-tagged peptides for
16 hr at 37C. The peptide exchange reaction was neutralized by adding
1/5 volume of 1M Tris pH 8.0.
2.3 | MAPS and flow cytometry
Following peptide exchange, 2 μg of each exchanged MHCII was incu-
bated with 100,000 streptavidin-coated microspheres (Bangs Labora-
tories, Fishers, IN) in 1% bovine serum albumin (BSA) for 1 hr at room
temperature. In parallel, an equivalent amount of DNP-tagged
peptide used in the peptide exchange reaction was incubated with
streptavidin-coated microspheres in the absence of MHCII for calcu-
lating the MAPS signal. After loading, the microspheres were washed
in 1% BSA and stained with 2 ng/μL of rat anti-DNP antibody (Clone
LO-DNP-2, Invitrogen) for 30 min at room temperature. Stained
microspheres were washed in 1% BSA and stained with 2 ng/μL of
secondary goat-anti-rat PE (Invitrogen) for 30 min at room tempera-
ture. The stained microspheres were then washed twice in 1% BSA
and resuspended in 500 μL for analysis by flow cytometry. Flow cyto-
metry was performed by gating on the population of single micro-
spheres and analyzing the median fluorescence intensity (MFI) from
the DNP fluorescent staining. The MAPS signal was determined by
normalizing the peptide-MHCII DNP MFI by the MFI of the micro-
spheres incubated with the peptide alone. This normalization
accounted for nonspecific binding of peptides to the streptavidin-
coated microspheres. Peptide-MHCII interactions exhibiting a MAPS
signal >5 were defined as binding interactions as this threshold results
in a false-positive rate of <5% (see details in the Section 3).
2.4 | IEDB peptide-MHCII binding prediction
IEDB peptide-MHCII binding predictions were performed by entering
each 20mer peptide sequence and predicting its binding to
DRB1*01:01, DRB1*04:01, DRB1*07:01, and DRB1*15:01 using the
IEDB recommended prediction method. The output data was broken
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down into six 15mers for each 20mer sequence provided. The IEDB
consensus method33,48 was used to predict peptide MHCII binding,
which provided a binding percentile rank for each 15mer. The percen-
tile rank binding score was calculated by comparing the predicted
peptide-MHCII binding affinity of the target peptide against 5 million
random 15mers from the SWISSPROT database. Accordingly, a low
percentile rank indicated a high predicted binding affinity while a high
percentile rank indicated a low predicted binding affinity. The lowest
percentile rank from the six 15mers derived from each single 20mer
sequence was selected as the binding score for the 20mer. Peptides
were said to be binders if the percentile rank was less than or equal to
20, in accordance with a previous study concerned with promiscuous
MHCII-binding peptides.49
2.5 | Structural analysis
PyMOL50 was used to make the structural images of the Zika Virus E
protein (PDB:5JHM)1 and the rotavirus VP7 protein. The comparative
model for the VP7 protein was generated with SWISS-MODEL51 and
used Chain A from the PDB:3FMG for the template.52
3 | RESULTS
3.1 | MAPS strategy and validation
MAPS is performed by first expressing a diverse panel of human
MHCII alleles in insect cells (Figure 1, Step 1a). The alpha chain (DRA)
of each MHCII was fused to a biotinylation site and each beta chain
allele (DRB1*01:01 – DR1, DRB1*04:01 – DR4, DRB1*07:01 – DR7,
DRB1*15:01 – DR15) was fused to the invariant chain peptide CLIP
via a cleavable thrombin linker.46,53 The cleavable linker allows the
invariant CLIP peptide to be exchanged for any peptide of interest, all-
owing a single MHCII-CLIP construct to be used to measure thou-
sands of unique peptide-MHCII binding events in a high throughput
manner. The alpha and beta chains of each MHCII construct were also
fused to the leucine zipper dimerization motifs Fos and Jun, respec-
tively, to stabilize the heterodimer during peptide exchange.45 The
four MHCII alleles chosen in this study are expected to cover approxi-
mately 34% of the U.S. population based on known MHCII allele fre-
quencies54 and demographic data (Figure S1a). Following purification,
each MHCII-CLIP heterodimer was biotinylated and the degree of
biotinylation was assessed by a streptavidin (SAv) shift assay and all
alleles were >98% biotinylated (Figure S1b). Thrombin-linker cleavage
was evaluated similarly (Figure S1c), and the reduction in the size of
the beta chain of each allele confirmed CLIP dissociation.
In parallel with MHCII expression and purification, an overlapping
peptide library is synthesized to be screened for binding to each MHCII
allele (Figure 1, Step 1b). Each peptide library consists of dinitrophenyl-
(DNP) tagged 20mers with 10 amino acid overlaps. These DNP-tagged
20mers are then exchanged for the CLIP peptide (Figure 1, Step 2) and
loaded onto ~4 μm diameter SAv-coated microspheres (Figure 1,
Step 3). Once loaded, the microspheres are stained for the DNP-tagged
peptide using fluorescently labeled anti-DNP antibody and then ana-
lyzed using flow cytometry (Figure 1, Steps 4 and 5), where the fluores-
cent DNP-peptide staining should correlate with binding affinity.
As a proof of concept, we first tested MAPS using the well-
characterized interaction between DR1 and the influenza peptide
HA306-318 tagged with DNP (DNP-PKYVKQNTLKLAT, PBR in bold).
DR1-bound CLIP was exchanged with HA306-318, and the resulting pep-
tide exchange mixture was analyzed by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE). It has been shown that
DR1 without any peptide occupying the peptide binding groove (empty
F IGURE 1 MAPS involves three phases: prepare, load, and analyze. The preparation phase involves (1a) purifying and biotinylating a panel of
diverse human MHCII alleles and (1b) synthesizing an overlapping DNP-tagged peptide library. The loading phase involves (2) loading the DNP-
tagged peptides from the library onto each MHCII allele via peptide exchange, and (3) loading the biotinylated, peptide-exchanged MHCII on
streptavidin-coated microspheres. The analysis phase involves (4) staining the loaded microspheres for the DNP-tagged peptide and (5) analyzing
resulting signal using flow cytometry. DNP, dinitrophenyl; MAPS, microsphere-assisted peptide screening [Color figure can be viewed at
wileyonlinelibrary.com]
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DR1) and DR1-CLIP molecules are not stable in SDS; however, DR1
binding of HA306-318 promotes SDS stability by protecting a sensitive site
in the DR1 peptide-binding groove from SDS.55 As expected, both the
empty DR1 (generated in this study by cleaving the thrombin linker in
the DR1-CLIP without adding any peptide) and the DR1-CLIP molecules
dissociated into their respective alpha- and beta-chains in the presence
of SDS while DR1-HA306-318 migrated as an SDS-stable heterodimer
(Figure 2a), indicating efficient peptide exchange.
After confirming the successful CLIPàHA306-318 peptide exchange
in DR1, we used MAPS to measure the anti-DNP fluorescence of micro-
spheres loaded with the DR1-HA306-318 peptide exchange mixture.
When analyzed using flow cytometry, DR1-HA306-318 microspheres
exhibited significantly greater DNP staining than microspheres loaded
with either empty DR1 or the HA306-318 peptide alone (Figure 2b), con-
firming that DNP staining is specific and peptide-MHCII binding depen-
dent. While MAPS successfully stained the DR1-HA306-318 complexes,
the incomplete shift (i.e., 37.9%) of the DNP-positive beads was surpris-
ing given the close to 100% peptide exchange efficiency observed in
Figure 2a and the high binding affinity between DR1 and the HA306-318
peptide (IC50 ~34 nM).
36 This apparent inconsistency led us to hypothe-
size that the position of the 9mer PBR relative to the DNP tag might
affect the accessibility of the DNP tag during antibody staining. For
example, if the PBR is located at the N-terminus of a given peptide, the
beta-sheet and alpha helices of the peptide-binding groove might
obstruct antibody binding to the DNP tag, resulting in a lower signal. To
test this hypothesis, we synthesized 12 DNP-tagged 20mers (Figure 2c,
right panel), in which the relative position of the HA306-318 PBR was
shifted from the N-terminus (relative PBR position of 1) to the C-
terminus (relative PBR position of 12). The remaining residues were
mutated to alanine to minimize complex interactions with peripheral
flanking residues.
The relative MAPS signal for each PBR-variant of the HA306-318
peptide was normalized such that the signal observed equals one
when the PBR is at the N-terminus (relative PBR position of 1). As
expected, the relative MAPS signal was dependent on the position of
the PBR within the peptide (Figure 2c, left panel). The relative MAPS
signal was highest when the PBR was positioned near the middle of
the 20mer peptide (between residues seven and 10), which resulted
in up to 2.5 times greater signal than when the PBR was located at
the N-terminus. Interestingly, the relative MAPS signal decreased
approximately fivefold from its maximum when the PBR was posi-
tioned at the C-terminus of the peptide, suggesting that the accessi-
bility of the DNP tag might also be obstructed when the N-terminus
of the peptide is significantly overhanging, or that peptides with a C-
F IGURE 2 Validation of MAPS strategy with DR1-HA306-318 interaction. (a) SDS-PAGE analysis of the SDS-stability of various DR1
complexes. After thrombin cleavage of the CLIP peptide in the DR1-CLIP protein, the target HA306-318 peptide was added to allow
DR1-HA306-318 complex formation through peptide exchange, or no peptide was added (empty DR1) as a control. (b) Flow cytometry dot plots of
DNP-signal detected on microspheres loaded with: empty DR1 (left), HA306-318 peptide alone (middle), or DR1-HA306-318 (right). (c) Relative
MAPS signal plotted with respect to the relative position of the HA306-318 PBR within a 20mer peptide. The peripheral flanking residues were
mutated to alanine. Relative MAPS signal represents the MAPS signal of each peptide normalized by the MAPS signal observed for the peptide
with a relative PBR position of 1. DNP, dinitrophenyl; MAPS, microsphere-assisted peptide screening; PBR, peptide binding register [Color figure
can be viewed at wileyonlinelibrary.com]
SMITH ET AL. 5 of 12
terminal PBR do not bind MHC molecules strongly. While we investi-
gated the effect of the PBR position on binding for a single peptide-
MHC pair, we anticipate that other pairs would behave similarly.
Even though the MAPS signal was found to be sensitive to the rel-
ative position of the PBR within a given peptide, the actual number of
missed binding peptides with unique PBRs should be minimal when
screening overlapping peptides because most unique PBRs will appear
twice (i.e., in consecutive, overlapping peptides). In addition, although
the sensitivity of MAPS to the relative PBR position tends to
reduce the overall accuracy of the approach, this sensitivity could
have unanticipated advantages. For example, MAPS used in conjunc-
tion with more rigorous protein–protein binding assays could help
identify unique PBRs within a particular binding peptide, which is a
significant obstacle to improving the accuracy of computational
peptide–MHCII binding predictions.30
3.2 | Evaluating MAPS performance with AhpC
reference peptide library
After validating the MAPS strategy with DR1-HA306-318 and observ-
ing its sensitivity to the PBR position, we next aimed to evaluate the
overall accuracy of MAPS. To this end, a 16-peptide library of over-
lapping 20mers (Figure S2a) with known binding affinity to each
MHCII allele in our panel (DR1, DR4, DR7, and DR15) was synthe-
sized based on the alkyl hydroperoxide reductase (AhpC) protein of
B. pseudomallei.56 MAPS was performed for each AhpC peptide–
MHCII combination, and binding was quantified as the MAPS signal,
which was defined as the ratio of the median fluorescence intensity
(MFI) of the DNP-tagged peptide bound to MHCII (e.g., Figure 2b,
right panel) over the MFI of the DNP-tagged peptide incubated with
SAv-microspheres without MHCII (e.g., Figure 2b, middle panel). The
MAPS signal of each peptide–MHCII combination was then plotted
with respect to the known IC50 value
56 of the peptide as shown in
Figure S2b. The general inverse relationship observed between the
MAPS signal and the IC50 value indicates that the MAPS signal largely
correlates with peptide–MHC binding affinity. Although the MAPS
strategy is generally accurate, we observed that MAPS missed some
known binding peptides within the AhpC peptide library (i.e., peptides
known to bind a particular MHCII allele, but exhibited a low MAPS
signal). Taken together, these results demonstrate that the MAPS sig-
nal provides a semiquantitative measure of peptide-MHC binding
affinity and is susceptible to false-negatives. These missed binders are
likely a consequence of MAPS sensitivity to PBR position (Figure 2c),
which suggests that the missed binders have either N-terminal or C-
terminal PBRs.
The AhpC reference peptide library was also screened for predicted
binding to each MHCII allele using the in silico bioinformatics tools pro-
vided by IEDB.35 Peptide-MHCII binding was predicted using the IEDB
recommended consensus method,33 which combined the predictions
provided by the stabilized matrix method SMM-align,22 the artificial neu-
ral network-based method NN-align,29 and either the Sturniolo19 method
or the combinatorial library (CombLib)48 method. The binding score of
the consensus prediction was given as a percentile rank, which scores
each peptide's predicted binding affinity against the binding affinities of
5 million random 15mers from the SWISSPROT database. Peptides given
a low percentile rank were predicted to be strong binders while peptides
given a high percentile rank were not predicted to interact strongly with
that particular MHCII allele. We defined a predicted binder as a peptide
with a percentile rank of less than or equal to 20, in line with previous
studies of promiscuous MHCII-binding peptides.49 The accuracy of the
IEDB binding predictions were then compared to the experimental
results using MAPS by plotting the respective ROC curve of each
(Figure 3). Based on this analysis, the AUC for the MAPS ROC curve
was found to be approximately 0.851, while the AUCs for the pre-
dictor ROCs were significantly lower, ranging from 0.615 for the
SMM-Align method to 0.741 for the NN-Align method. The IEDB
consensus method, which combines the output of the SMM-Align
method and the NN-Align method yielded an AUC of 0.694. These
results indicate that while the MAPS strategy is susceptible to false-
negatives depending on the relative position of the PBR within a
peptide, it significantly outperforms the predictions provided by
IEDB for 20mer peptide-MHCII binding. Based on the ROC analysis,
peptide-MHCII interactions producing a MAPS signal >5 were classi-
fied as binding peptides in this study, as this threshold results in a
false-positive rate of <5%.
3.3 | MAPS of Zika virus envelope protein
After quantifying the overall accuracy of the MAPS strategy and
defining a peptide-binding threshold using the AhpC reference library,
we next aimed to identify promiscuous MHCII-binding peptides
within the Zika virus E protein. We synthesized a 37-peptide library of
overlapping DNP-tagged 20mers from the Zika virus E protein (ZikVE)
(Figure S3). Each ZikVE peptide was exchanged into the four MHCII
alleles, and the resulting peptide-MHCII binding was measured by
MAPS (Figure 4a). Of the four alleles screened, DR1 bound the most
F IGURE 3 ROC analysis of MAPS strategy compared to IEDB
peptide-MHCII binding predictors for the AhpC reference peptide
library. The AUC of each curve is provided in the legend. AUC, area
under curve; IEDB, Immune Epitope Database and Analysis Resource;
MAPS, microsphere-assisted peptide screening; ROC, receiver operating
characteristic [Color figure can be viewed at wileyonlinelibrary.com]
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ZikVE peptides (49%), followed by DR4 (41%), DR7 (35%), and DR15
(30%) (Figure 4b). Based on the criterion that promiscuous MHCII-
binding peptides exhibit a MAPS signal >5 for all four MHCII alleles,
five (~14%) promiscuous MHCII-binding peptides within the E protein
library (Figure 4c) were identified: ZikVE51-70, ZikVE131-150, ZikVE191-210,
ZikVE311-330, ZikVE351-370 (Figures 4a and 5a). Of the five promiscuous
MHCII-binding ZikVE peptides identified by MAPS, only two
(ZikVE131-150 and ZikVE351-370) were predicted to bind all four alleles by
the IEDB consensus prediction (Table S1). Interestingly, only DR4 was
predicted to bind all five promiscuously binding peptides using the IEDB
consensus method. Together these results provide further evidence that
the IEDB consensus method for predicting promiscuous 20mer peptide-
MHCII binding is generally inaccurate and that MAPS is able to identify
promiscuous binders missed by computational methods.
F IGURE 4 MAPS analysis of
overlapping peptides from Zika virus E
protein for four human MHCII alleles.
(a) MAPS signal of each ZikVE peptide.
Data are shown as the mean of two
independent experiments. Error bars
signify standard deviation. Dashed lines
represent the peptide-binding threshold
of MAPS signal of 5. For the heat map,
orange and red indicate MAPS signals of
5–30 and >30, respectively. (b) Pie-charts
representing the percentage of ZikVE
peptides that bound to each MHCII allele.
Colored slices represent the fraction of
binders. (c) A pie-chart representing the
fractions of ZikVE peptides binding 0, 1,
2, 3, or 4 MHCII alleles. MAPS,
microsphere-assisted peptide screening
[Color figure can be viewed at
wileyonlinelibrary.com]
F IGURE 5 Structural analysis
of MAPS-identified promiscuous
MHCII-binding peptides in the
Zika virus E protein. (a) MAPS
signal for each promiscuous
MHCII-binding E protein peptide.
Dashed lines represent the
peptide-binding threshold of
MAPS signal of 5. E protein
structural analysis of (b) the
3 protein domains, (c) the five
promiscuous MHCII-binding
peptides as well as the quasi-
promiscuous peptide
ZikVE391-410 identified by MAPS
and (d) the B cell epitopes
reported previously.5,57 In (d), the
residues of the B cell epitopes
overlapping with the promiscuous
MHCII-binding peptides are in
black, and the nonoverlapping
residues are in teal. In (c) and (d),
only EDIII is shown in the image
on the left for clarity. MAPS,
microsphere-assisted peptide
screening [Color figure can be
viewed at wileyonlinelibrary.com]
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Furthermore, all five of the MAPS-identified promiscuous MHCII-
binding ZikVE peptides have been reported to be true CD4+ T cell
epitopes in human-DR transgenic mouse models.14 Given their immu-
nological relevance as T cell epitopes, we further explored the immuno-
genicity of these ZikVE peptides by analyzing their position within the
folded E protein. In contrast to other flaviviruses, a Zika virus vaccine
does not currently exist. Therefore, limited information of antibody
neutralization sites on a vaccine strain is available as a point of compari-
son. However, it is well documented that antibodies binding the EDIII
domain tend to be potently neutralizing and less prone to ADE than anti-
bodies binding the EDI and EDII domains.2 Analyzing the position of each
promiscuous MHCII-binding ZikVE peptide within the structure of the E
protein revealed that one promiscuous MHCII-binding peptide is within
the EDI domain (ZikVE131-150), while two are within the EDII (ZikVE51-70
and ZikVE191-210) and EDIII domains (ZikVE311-330 and ZikVE351-370)
(Figure 5b,c).
While information regarding specific antibody-contacting residues
on the ZikVE protein is still emerging, a 2017 study5 reported that a
neutralizing antibody in Zika-infected individuals contacted residues
A311, T351, and L352, among others on the E protein. These
residues overlap with the EDIII promiscuous MHCII-binding peptides
ZikVE311-330 and ZikVE351-370 (Figure 5d). Moreover, the same study
5
also reported that mutating the lysine at residue 394 to alanine elimi-
nated antibody binding, suggesting that antibody recognition of K394
is critical for neutralization. While the relevant peptide ZikVE391-410
did not fulfil our criterion as a promiscuous MHCII-binding peptide, it
exhibited a MAPS signal >5 for three of the four alleles tested (DR1,
DR4, and DR7, See Figure 4a). If we include ZikVE391-410 as a quasi-
promiscuously binding peptide in our analysis, eight of 18 reported5
antibody neutralization sites on the ZikVE protein were also present
in promiscuous MHCII-binding ZikVE peptides (Figure 5d). Similarly,
another study57 reported that antibodies contacting residues M68,
S70, V153, T315, and P354 (among others) were potently cross neu-
tralizing to Dengue and Zika virus. In addition to the T315 and P354
residues found in the promiscuous MHCII-binding EDIII peptides
ZikVE311-330 and ZikVE351-370, M68 and S70 are found in the promis-
cuous MHCII-binding EDII peptide ZikVE51-70 (Figure 5d). In total, six
of the 16 E protein residues responsible for the polar and salt-bridge
antibody contacts57 are also present in the MAPS-identified promis-
cuous MHCII-binding ZikVE peptides. The observed overlap between
promiscuous MHCII-binding ZikVE peptides identified by MAPS and
antibody neutralization sites on the Zika virus E protein (Figure 5d)
was striking and could have important implications in the design of
peptide-based vaccines and diagnostic tools for Zika virus.
3.4 | MAPS of rotavirus outer capsid
glycoprotein VP7
The significant overlap between promiscuous MHCII-binding pep-
tides and antibody neutralization sites observed for the ZikVE pro-
tein was unexpected. However, in-depth studies involving the
immune response to Zika virus are relatively recent, and our under-
standing of T cell epitopes and B cell epitopes (BCEs) within the
ZikVE protein is still developing. To determine if this phenomenon
is unique to the ZikVE protein, we next synthesized a 25-peptide
library of overlapping 20mers derived from the well-characterized
rotavirus outer capsid glycoprotein VP7 (Figure S4) and performed
similar analyses.
Rotavirus is the most common cause of diarrheal disease in chil-
dren worldwide,58 and remains a significant health challenge in devel-
oping countries despite being extensively characterized and the target
of two approved vaccines.59,60 Each 20mer in the VP7 peptide library
F IGURE 6 MAPS analysis of
overlapping peptides from VP7
protein for four human MHCII
alleles. (a) MAPS signal of each
VP7 peptide. Data are shown as
the mean of two independent
experiments. Error bars signify
standard deviation. Dashed lines
represent peptide-binding
threshold of MAPS signal
of 5. For the heat map, orange
and red indicate MAPS signals of
5–30 and >30, respectively.
(b) Pie-charts representing the
percentage of VP7 peptides that
bound to each MHCII allele.
Colored slices represent the
fraction of binders. (c) A pie-chart
representing the fraction of VP7
peptides binding 0, 1, 2, 3, or
4 MHCII alleles. MAPS,
microsphere-assisted peptide
screening [Color figure can be
viewed at wileyonlinelibrary.com]
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was exchanged into the four MHCII alleles, and peptide-MHCII bind-
ing was evaluated by MAPS (Figure 6a). DR4 bound the most VP7
peptides (65%) followed by DR1 (61%), DR7 (54%), and DR15 (42%)
(Figure 6b). Interestingly, more VP7 peptides tended to bind promis-
cuously than the ZikVE peptides screened (See Figures 4c and 6c),
potentially related to its wider spread in humans. Based on the criteria
that promiscuous MHCII-binding peptides exhibit a MAPS signal >5
for all four MHCII alleles, seven promiscuous MHCII-binding peptides
within the VP7 protein were identified: VP741-60, VP771-90, VP781-100,
VP7111-130, VP7211-230, VP7251-270, and VP7301-320 (Figures 6a and
7a). Of these seven promiscuous MHCII-binding peptides, only four
were predicted to bind all four alleles by the IEDB consensus predic-
tion (Table S2). Further, similar to the promiscuous MHCII-binding
ZikVE peptides, only DR4 was predicted to bind all seven MAPS-
identified promiscuous MHCII-binding VP7 peptides using the IEDB
consensus method. Taken together, these results further suggest that
in silico strategies alone remain insufficient to reliably predict peptide-
MHCII binding.
To investigate any potential overlap between the promiscuous
MHCII-binding VP7 peptides identified by MAPS and antibody neutrali-
zation sites on the folded VP7 protein, a structural analysis was per-
formed. In contrast to Zika virus, for which no vaccine exists and little
data regarding dominant antibody neutralization sites on the E protein is
available, two vaccines for rotavirus have been licensed and the antibody
neutralization sites on the VP7 protein are well characterized. VP7 pro-
tein contains three dominant antigenic epitopes: 7-1a (BCE 1), 7-1b
(BCE 2), and 7–2 (BCE 3),52 all of which are located near the interface of
separate VP7 trimer units. Interestingly, three of the seven promiscuous
MHCII-binding VP7 peptides (VP781-100, VP7111-130, VP7211-230) identi-
fied by MAPS overlapped with these dominant antigenic epitopes
(Figure 7b,c). The most striking overlap was observed for VP781-100,
which included eight of the 14 residues of BCE 1. Further, VP781-100 and
VP7111-130 together cover nearly all of BCE 1, overlapping with 12 of the
14 residues (Figure 7d). The VP7211-230 peptide that was associated with
the greatest MAPS signal also overlapped with dominant antigenic epi-
topes, albeit to a lesser extent, sharing three of the six residues of BCE
2 and two of the nine residues of BCE 3 (Figure 7d). Therefore, as with
the promiscuous MHCII-binding ZikVE peptides, we observed consider-
able overlap between the promiscuous MHCII-binding VP7 peptides and
antibody neutralization sites on the folded VP7 protein (Figure 7c). These
surprising results hint at a deeper relationship between acquired B cell
and T cell specificity during viral infection.
4 | DISCUSSION
Viral infections and their vaccination are often studied in the context
of a neutralizing antibody response; however, CD4+ T cells also play a
critical role in viral immunity.61 Therefore, identifying T cell epitopes
F IGURE 7 Structural analysis of MAPS-identified promiscuous MHCII-binding VP7 peptides. (a) MAPS signal for each promiscuous MHCII-
binding VP7 peptide. VP7 structural analysis (b) of the promiscuous MHCII-binding peptides VP781-100, VP7111-130, and VP7211-230, and (c) the
B cell epitopes (BCEs) reported previously.52 In (c), the residues of the BCEs overlapping with the promiscuous MHCII-binding peptides
VP781-100, VP7111-130, or VP7211-230 are in black, and the nonoverlapping residues are in teal. (d) Amino acid sequence overlaps between the
three dominant BCEs on the VP7 protein and the promiscuous MHCII-binding peptides VP781-100, VP7111-130, and VP7211-230. Overlapping
residues are indicated in red. MAPS, microsphere-assisted peptide screening [Color figure can be viewed at wileyonlinelibrary.com]
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is an important part of understanding how viral antigens are
processed and presented, as well as predicting which viral protein
fragments are likely to be recognized by T cells.
Early findings have suggested that, in contrast to other flaviviruses
in which T cell epitopes are primarily located on nonstructural pro-
teins (NS), T cell epitopes in Zika virus appear to be located on struc-
tural proteins including the E protein.2,8 Here, we screened an
overlapping peptide library derived from the Zika virus E protein for
binding to four common human MHCII alleles and identified five
promiscuous MHCII-binding peptides (ZikVE51-70, ZikVE131-150,
ZikVE191-210, ZikVE311-330, ZikVE351-370). Interestingly, a 2018 study
14
aiming to identify T cell epitopes in the Zika virus E protein found that
ZikVE51-70, ZikVE131-150, and ZikVE191-210 existed as CD4
+ T cell epi-
topes in HLA-DR4 transgenic mice primed with 25 μg of recombinant
Zika envelope protein. Similarly, ZikVE131-150 and ZikVE311-330 were
also shown to be CD4+ T cell epitopes in HLA-DR1 and HLA-DR15
transgenic mice, respectively.14 Further, when mice were challenged
with Zika virus, the CD4+ T cell response to ZikVE351-370 was among
the strongest as measured by IFNγ ELISpot. Therefore, all five of the
promiscuous MHCII-binding ZikVE peptides identified using MAPS
are indeed T cell epitopes in either humans or transgenic animal
models. Moreover, while the aforementioned study14 included DR1,
DR4, and DR15, our results confirm that these peptides (ZikVE51-70,
ZikVE131-150, ZikVE191-210, ZikVE311-330, and ZikVE351-370) also bind
DR7, which provides broader coverage to Hispanic and African Ameri-
can populations (10.5% and 9.8%, respectively).
In addition to identifying five promiscuous MHCII-binding ZikVE
peptides, we observed a striking overlap between these peptides and
previously reported antibody neutralization sites on the ZikVE pro-
tein5,57 (Figure 5c,d). Interestingly, a similar overlap between regions
of the Dengue E protein recognized by CD4+ T cells and those
targeted by IgG molecules has also been reported elsewhere.62 How-
ever, this paired antigen specificity does not appear to be unique to
flaviviruses, as it was also observed in this study for the rotavirus VP7
protein (Figure 7b–d), and has been described elsewhere for a model
E. coli antigen,63 suggesting a deeper relationship between B cell
receptor (BCR) binding and antigen presentation to CD4+ T cells.64
One explanation for the shared B cell/T cell antigen specificity is that
BCR bound residues on the antigenic protein are protected from deg-
radation during B-cell antigen processing.64 If these BCR-protected
residues are derived from a virus structural protein, they will likely be
internalized and presented on MHCII during virus infections, which
would preferentially expand CD4+ T cells of the same or similar speci-
ficity.62 Regardless of the exact mechanism, shared B/T cell specificity
creates the possibility of predicting CD4+ T cell epitopes from known
antibody neutralization sites and vice versa, which could be relevant
to the design of highly immunogenic vaccines in the future.65
While we demonstrated the MAPS strategy using pathogenic pep-
tide libraries, high-throughput methods for identifying MHCII-binding
peptides are also relevant to the development of peptide-based tools
and therapeutics for treating cancer,66,67 and autoimmune condi-
tions.68 Ultra high-throughput computational tools have come a long
way in the past two decades; however, reliably predicting peptide-
MHCII binding in silico remains a challenge.33 This challenge arises
largely from the open-ended peptide-binding groove of MHCII mole-
cules, which allows for the presentation of variable-length peptides
with a number of possible peptide conformations and secondary
interactions that are difficult to predict. In addition, MHCII are charac-
terized by substantial allelic diversity, which is manifested in the
peptide-binding grooves of different MHCII alleles.
The MAPS strategy reported here provides a more accurate, high-
throughput peptide-MHCII screening strategy that seeks to balance
the throughput of computational systems and the quantitative detail
of more conventional peptide-binding assays. MAPS is best suited for
situations where a handful of pathogenic proteins with known
sequences have been identified because MAPS scales linearly with
the number of pathogenic proteins screened but is much higher
throughput than conventional experimental methods used to identify
peptide-MHCII binders.69 While quantitative binding data is critical to
improving the accuracy of computational peptide-MHCII binding pre-
dictors, this data alone provides an incomplete picture of peptide-
MHCII binding. Identification of the 9mer PBR core that facilitates the
principle interaction between a peptide and an MHCII molecule is also
important. In fact, PBR identification is one of the greatest challenges
associated with predicting peptide-MHCII binding.54 Although the
MAPS strategy described here was designed to rapidly identify pro-
miscuous MHCII-binding peptides, the method used to detect peptide
binding was found to be sensitive to the relative position of the PBR
core within 20mer peptides (Figure 2c). While this unforeseen sensi-
tivity complicates the translation of the observed MAPS signal to
peptide-MHC binding affinity, it does provide some insight into the
location of the PBR. As a result, MAPS coupled with quantitative mea-
surements of peptide-MHCII binding affinity might provide a basis for
the informed prediction of the PBR within a 20mer peptide.
The emergence of Zika virus and the consequent epidemiological
crisis underscores the need for deployable, high-throughput systems
capable of rapidly characterizing the immune responses to viral infec-
tion, which includes identifying relevant peptide-MHCII interactions.
The MAPS strategy introduced here addresses such a need by provid-
ing a simple method for identifying immunologically relevant, promis-
cuous MHCII-binding peptides. Incorporation of the MAPS strategy
into the vaccine development process could accelerate T cell epitope
identification and expedite the development and manufacturing of
novel vaccines.70 Beyond vaccine development, our observations indi-
cate that MAPS and similar screening strategies should provide valu-
able insights relevant to broadly applicable peptide-based therapies,
vaccines, and diagnostic tools necessary to protect ethnically diverse
populations.
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